Aclaris Therapeutics (ACRS) Enterprise Value: 2017-2025
Historic Enterprise Value for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $109.9 million.
- Aclaris Therapeutics' Enterprise Value rose 340.65% to $109.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$208.8 million, marking a year-over-year increase of 48.32%. This contributed to the annual value of $63.6 million for FY2024, which is 242.09% up from last year.
- Latest data reveals that Aclaris Therapeutics reported Enterprise Value of $109.9 million as of Q3 2025, which was up 103.73% from $54.0 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Enterprise Value peaked at $1.2 billion during Q1 2021, and registered a low of -$45.7 million during Q3 2024.
- For the 3-year period, Aclaris Therapeutics' Enterprise Value averaged around $135.2 million, with its median value being $59.8 million (2025).
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 234,502.03% in 2021, then tumbled by 111.96% in 2024.
- Aclaris Therapeutics' Enterprise Value (Quarterly) stood at $698.8 million in 2021, then increased by 19.15% to $832.7 million in 2022, then tumbled by 105.37% to -$44.7 million in 2023, then spiked by 242.09% to $63.6 million in 2024, then soared by 340.65% to $109.9 million in 2025.
- Its Enterprise Value stands at $109.9 million for Q3 2025, versus $54.0 million for Q2 2025 and $59.8 million for Q1 2025.